ArticleCureus2026
Cholecalciferol Supplementation and Transplant Outcomes Across Immunosuppressive Regimens in Renal Transplant Recipients Using the United States Food and Drug Administration Adverse Event Reporting System.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Renal transplant recipients (RTRs) are highly susceptible to vitamin D deficiency because of chronic kidney disease and recommendations for sun avoidance. Cholecalciferol supplementation is frequently prescribed in combination with immunosuppressive therapy; however, comparative safety and efficacy profiles across immunosuppressive regimens remain insufficiently characterized. Objectives This study evaluated disproportionality in the reporting of transplant outcome events associated with cholecalciferol supplementation among RTRs receiving different immunosuppressive regimens, using data from the United States Food and Drug Administration Adverse Event Reporting System (FAERS). Methodology FAERS data (2004Q1-2025Q4) were analyzed to identify RTRs with and without cholecalciferol exposure. To minimize confounding from concomitant medications, comparisons were restricted to regimen pairs differing only in cholecalciferol inclusion. Reporting odds ratios (RORs) and adjusted RORs (aRORs) were calculated using univariate and multivariate logistic regression to evaluate disproportionate reporting of transplant outcome events (e.g., complications of transplanted kidney, graft dysfunction, graft loss, rejection). Results Among 26,002 RTRs, cholecalciferol-added regimens were compared with their cholecalciferol-naive counterparts within each immunosuppressive regimen. In the calcineurin inhibitor (CNI) + steroid (STR) + antimetabolite (ANT) regimen, cholecalciferol addition was associated with significantly lower reporting of transplant outcome events than CNI + STR + ANT without cholecalciferol (ROR: 0.565 (95% confidence interval (CI): 0.382-0.836),
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.